Imunon, INC 10-Q quarterly reports

Imunon, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Imunon, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.2 million and continued progress in its Phase 3 OVATION 3 ovarian cancer trial.

Imunon, Inc. reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead ovarian cancer immunotherapy into Phase 3 and presenting positive Phase 2 data, despite ongoing going concern doubts.

Imunon reported a reduced net loss and positive clinical data for its lead ovarian cancer immunotherapy, IMNN-001, while addressing significant going concern and Nasdaq listing challenges.

Imunon, Inc. announces its financial results for the first quarter of 2025, highlighting advancements in its IMNN-001 ovarian cancer treatment and IMNN-101 COVID-19 vaccine programs, while also acknowledging substantial doubt about its ability to continue as a going concern.

Imunon, a clinical-stage biotechnology company, announced positive topline results from its Phase II OVATION 2 study of IMNN-001 in advanced ovarian cancer, along with a financial update for the third quarter of 2024.

Imunon reports positive topline results from its Phase II OVATION 2 study for its lead drug candidate, IMNN-001, and provides a financial update for the second quarter of 2024, highlighting a net loss of $9.7 million for the first six months of the year.

Imunon Inc. reported a net loss of $4.9 million for the first quarter of 2024, with ongoing concerns about its ability to continue as a going concern.